T
Tenax Therapeutics, Inc. (TENX)
NCM – Real Time Price. Currency in USD
12.17
+0.22 (1.84%)
At close: May 12, 2026, 4:00 PM EDT
12.17
0.00 (0.00%)
After-hours: May 12, 2026, 5:42 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
12.17
+0.22 (1.84%)
At close: May 12, 2026, 4:00 PM EDT
12.17
0.00 (0.00%)
After-hours: May 12, 2026, 5:42 PM EDT
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
| Name | Position |
|---|---|
| Dr. Douglas Hay Ph.D. | Executive Vice President of Regulatory Affairs |
| Dr. Stuart Rich M.D. | Chief Medical Officer & Director |
| Mr. Christopher T. Giordano | CEO, President & Director |
| Mr. Doug Randall | Chief Business Officer |
| Mr. Thomas A. McGauley | Interim CFO and Principal Financial Officer & Principal Accounting Officer |
| Mr. Timothy G. Healey M.B.A. | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-22 | DEF 14A | tennx-20260417.htm |
| 2026-04-22 | 8-K | d81080d8k.htm |
| 2026-03-24 | S-3 | tennx_s3.htm |
| 2026-03-10 | 8-K | tennx_8k.htm |
| 2026-01-09 | 8-K | tennx_8k.htm |
| 2025-12-17 | 8-K | tennx_8k.htm |
| 2025-11-12 | 8-K | tennx_8k.htm |
| 2025-09-16 | 8-K | tennx_8k.htm |
| 2025-09-09 | 8-K | tennx_8k.htm |
| 2025-08-13 | 8-K | tennx_8k.htm |